|
業務類別
|
Biotechnology |
|
業務概覽
|
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects. |
| 公司地址
| 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 405-4770 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.bridgebio.com |
| 員工數量
| 92 |
| Dr. Eli M. Wallace, PhD |
Director and Chief Executive Officer |
-- |
13/08/2025 |
| Dr. Yong Ben, M.D. |
Chief Medical and Development Officer |
-- |
13/08/2025 |
| Dr. Pedro J. Beltran, PhD |
Chief Scientific Officer |
-- |
13/08/2025 |
| Mr. Uneek Mehra |
Chief Financial Officer and Principal Accounting Officer |
-- |
13/08/2025 |
|
|
| Ms. Michelle Doig |
Independent Director |
13/08/2025 |
| Dr. Eli M. Wallace, PhD |
Director and Chief Executive Officer |
13/08/2025 |
| Ms. Bihua Chen |
Director |
13/08/2025 |
| Dr. Frank P. McCormick, D.Sc.,F.R.S.,PhD |
Independent Director |
13/08/2025 |
| Dr. Neil Kumar, PhD |
Director |
13/08/2025 |
| Dr. Praveen Tipirneni, M.B.A.,M.D. |
Independent Director |
13/08/2025 |
| Dr. Raymond Kelleher, M.D. |
Independent Director |
13/08/2025 |
| Mr. Jacob Bauer, M.B.A. |
Independent Director |
13/08/2025 |
|
|
|
|
